To further investigate the clinical relevance of this GSE1/TACSTD2 expression profile, we reanalyzed a pooled PCa dataset (n = 2205 samples) consisting of prostate cancer (DKFZ, Cancer Cell (2018)), prostate adenocarcinoma (MSKCC/DFCI, Nature Genetics (2018)), metastatic castration-sensitive prostate cancer (MSK, Clin Cancer Res (2020)), and metastatic prostate adenocarcinoma (SU2C/PCF Dream Team, PNAS (2019)) from the cBioPortal platform (https://www.cbioportal.org/, accessed on 13 December 2020). This evidence concerns the gene TACSTD2 and prostate carcinoma.